Printer Friendly

Further evidence on the effectiveness of potato juice in dyspeptic complaints.

Use of freshly squeezed potato juice for the treatment of hyperacidic stomach complaints became very popular in Europe when the Swiss physician Maximilian Bircher-Benner, born 1867 in Aarau, used it in his highly regarded private hospital and later in his sanatorium in Zurich (http://www.paracelsus.de/heilv/natur_223.html). However, the first systematic study of the effectiveness and tolerability of potato juice was performed, only recently, in 2004 (Chrubasik et al., 2005). We showed that consumption of 100 ml of potato juice (Biotta[R]), consumed before going to bed and soon after rising in the morning and also, if necessary, during the day relieved dyspeptic complaints as assessed on validated outcome measures--the gastrointestinal symptom profile (GIS, Holtmann et al., 2004) and a disease-specific quality of life measure QOLRAD, (Madisch et al., 2003)--as well as on a 5-point, self-rated, effectiveness Likert scale. The GIS and QOLRAD scores improved significantly by about 42% and 51%, respectively (ITT-analysis, p < 0.001); the absolute values changed from 11.5 [+ or -] 5.1 to 6.3 [+ or -] 5.3 (GIS) and 62.0 [+ or -] 25.7 to 32.0 [+ or -] 28.8 (QOLRAD). The GIS was improved by 60% or more in 16 patients, and in 18 the QOLRAD improved by 60% or greater. Twenty-six of the patients rated efficacy as good or very good. Poor treatment success was observed in 13 (GIS), 11 (QOLRAD) and 10 on the efficacy scale--not necessarily in the same patients (2 of the patients failed to complete the study and on the basis of ITT, were placed in the "poor" group). We therefore wanted to go on to obtain preliminary data, on whether a potato juice concentrate was more effective than the juice.

Biotta AG Tagerwilen produced a 5-fold concentrate of the potato juice (for HPLC see Chrubasik et al., 2005) for a pilot study carried out in Dniepropetrovsk, Ukraine. After the State Committee on Food Supplements approved the study, 6 men and 12 women suffering from dyspeptic complaints (Table 1) volunteered to take the potato juice concentrate, starting with 2 teaspoons/day (morning and evening or more, if necessary). Two patients dropped out, a patient who had no gastroscopic diagnosis withdrew his consent and another patient who suffered from dry cough prior to entry to this trial, the first dose of the concentrate was associated with a coughing attack, such that she decided not to continue with the treatment.

Three of the patients took 2 teaspoons/day of the concentrate, nine took 3 teaspoons/day and five consumed 3 tablespoons/day. Three outcome indicators were used. The GIS score, improvement in the worst rated GIS symptom (where more than 1 component had the same worst score before treatment, the 1 with the least improvement was chosen as the outcome variable) and self-rated efficacy. After 6 days, the GIS score had improved by 73 [+ or -] 32% (ITT, mean [+ or -] SD p < 0.001). The absolute GIS values improved from 12.8 [+ or -] 4.3 to 3.1 [+ or -] 3.7, the subjects' worst GIS symptom improved in 15 by a median score of 2 (Fig. 1). Of the 3 non-improvers, 2 were the patients who withdrew, and in the remaining one, of 6 GIS components which were rated as 2 at commencement of treatment, 5 had improved. The doses of the medication used did not correlate with either outcome variable, neither did age, nor sex, weight, BMI or the duration of acute or chronic symptoms. Fourteen patients improved their GIS by 60% or more and 10 patients rated the efficacy of the treatment as very good or good. Failure of the treatment was not observed in any of the patients.

[FIGURE 1 OMITTED]

This pilot trial indicates, that the 5-fold concentrate of potato juice may be more effective in alleviating dyspeptic complaints than ordinary potato juice. A confirmatory clinical study should now be carried out to compare their effectiveness.

References

Chrubasik, S., Chrubasik, C., Torda, T., Madisch, A., 2005. Efficacy and tolerability of potato juice in dyspeptic patients: a pilot study. Phytomedicine, in press.

Holtmann, G., Adam, B., Frote, E., Saadat-Gilani, K., Vinson, B., 2004. Validation of the gastrointestinal symptom score (GIS) in patients with functional dyspepsia. Z. Gastroenterol. 42, T1179.

Madisch, A., Kulich, K.R., Malfertheimer, P., Ziegle, K., Bayerdorffer, E., Miehlke, S., Labenz, J., Carlsson, J., Wiklund, I.K., 2003. Impact of reflux disease on general and disease-related quality of life--evidence from a recent comparative methodological study in Germany. Z. Gastroenterol. 41, 1137-1143.

S. Chrubasik*

Department of Forensic Medicine, University of Freiburg, Albertstr. 9, 79104 Freiburg, Germany

E-mail address: sigrun.Chrubasik@klinikum.uni-freiburg.de

S. Chrubasik*, T. Boyko, Y. Filippov

Department of Gastroenterology, Ukraine Academy of Medical Science, Dniepropetrovsk, Ukraine

E-mail address: tboyko@inbox.ru (T. Boyko)

T. Torda

School of Medical Sciences, University of New South Wales, Sydney, Australia

E-mail address: t.torda@unsw.edu.au
Table 1. Baseline characteristics of the 18 patients (mean [+ or -] SD,
or numbers of patients)

Age (yr) 48 [+ or -] 15
Weight (kg) 70 [+ or -] 18
Height (cm) 167 [+ or -] 9
Duration of chronic symptoms (mths) 105 [+ or -] 120
Duration of acute exacerbation (wks) 33 [+ or -] 51

Diurnal distribution of symptoms
Morning 5
Noon 10
Afternoon 1
Evening 10
At night 2
Continuous complaints 3
Intermittent complaints 15

Risk factors
Regular alcohol consumption 2
Regular nicotine consumption 3
Regular consumption of spices 3
Use of synthetic medications 3

Endoscopic diagnoses (multiple)
Gastroduodenitis 4
Reflux oesophagitis 11
Duodenal ulcer 2
Deformation after duodenal ulcer 1
Gastritis 2
No gastroscopy 1
COPYRIGHT 2006 Urban & Fischer Verlag
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2006 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Title Annotation:LETTER TO THE EDITOR
Author:Chrubasik, S.; Boyko, T.; Filippov, Y.; Torda, T.
Publication:Phytomedicine: International Journal of Phytotherapy & Phytopharmacology
Date:Sep 1, 2006
Words:921
Previous Article:Bioactivity-guided fractionation of Coronopus didymus: a free radical scavenging perspective.
Next Article:Potential molecular basis of the chondroprotective effect of Harpagophytum procumbens.
Topics:

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters